Generic Name and Formulations:
Naldemedine 0.2mg; tabs.
Indications for SYMPROIC:
Opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.
Take with or without food. 0.2mg once daily. Discontinue if opioid pain therapy is also discontinued.
Known or suspected GI obstruction. Patients at increased risk of recurrent obstruction.
Risk of GI perforation in those with conditions associated with reduction in structural integrity of the GI tract wall (eg, peptic ulcer disease, Ogilvie’s syndrome, diverticular disease, infiltrative GI tract malignancies, or peritoneal metastases). Monitor for abdominal pain; discontinue if severe, persistent, or worsening symptoms occur. Monitor for symptoms of opioid withdrawal (esp. patients having disruptions to the blood brain barrier). Severe hepatic impairment (Child-Pugh Class C): avoid. Pregnancy. Nursing mothers: not recommended (during and for 3 days after final dose).
Avoid concomitant strong CYP3A inducers (eg, rifampin, carbamazepine, phenytoin, St. John’s Wort) or other opioid antagonists. Potentiated by moderate (eg, fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and strong CYP3A inhibitors (eg, itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir), or P-gp inhibitors (eg, amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil); monitor.
Opioid antagonist (peripheral).
Abdominal pain, diarrhea, nausea, vomiting, gastroenteritis; opioid withdrawal.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|